Search

Brolucizumab

[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

Dinutuximab

Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. … neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Chromium gluconate

Chromium nicotinate

Potassium bitartrate

Potassium bitartrate has a long history of medical use as a laxative administered as a rectal suppository and is an approved third-class OTC drug in Japan. … Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]

Plasminogen

[A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.

Teprotumumab

approved by the FDA in January 2020 for the treatment of TED. … [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was

Lovotibeglogene autotemcel

have a history of vaso-occlusive events. … Specifically, lovotibeglogene autotemcel provides a functional copy of a modified beta-globin gene (β^A-T87Q-globin) that when combined with α-globin, produces hemoglobins with similar oxygen-binding

Atrasentan

Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

Altanserin

Altanserin has a monoisotopic molecular weight of 411.14 Da. … Altanserin is a small molecule drug. The usage of the INN stem '-anserin' in the name indicates that Altanserin is a serotonin receptor antagonist.